Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Conditions
Keywords
alopecia, breast cancer, hair loss, chemotherapy induced alopecia, 19-277, Memorial Sloan Kettering Cancer Center
Brief summary
This study is being done to determine if using the Paxman Scalp Cooling System at temperatures lower than the current standard is a safe and tolerable approach to prevent hair loss in breast cancer patients receiving chemotherapy.
Interventions
DEVICEPAXMAN Scalp Cooler
Scalp cooling will occur with each dose of chemotherapy.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age 18 years or older * New diagnosis of breast cancer stage I-IV * Planning to undergo neoadjuvant or adjuvant chemotherapy with curative intent * Chemotherapy must be planned for at least 4 cycles of full-dose anthracycline plus cyclophosphamide followed by taxane based chemotherapy regimen: * Concurrent trastuzumab at standard doses is allowed * Concurrent pertuzumab at standard doses is allowed * Administration of chemotherapy on a dose dense schedule is allowed as clinically indicated * For women of childbearing potential, a negative pregnancy test is needed within 7 days prior to study intervention, or whenever collected as per standard of care. For women who undergo fertility preservation or ovarian stimulation, a negative pregnancy test is not needed and eligibility due to positive pregnancy test will be determined by investigator discretion.
Exclusion criteria
* Any other concurrent malignancy including hematological malignancies (i.e. leukemia or lymphoma) * Baseline alopecia (defined CTCAE v5.0 grade \> 1) * Subjects who are scheduled for bone marrow ablation chemotherapy * Male gender * Age \>/= 75 years * Personal history of migraines, cluster or tension headaches as defined as actual medical diagnosis by a physician and/or prescribed medications. If personal history of migraines was related to a past medical problem that is now resolved, subject may go on study at the discretion of the Principal Investigator. * Subjects who have had prior chemotherapy * Subjects who have had \>/=1 previous chemotherapy exposure resulting in alopecia * An existing history of scalp metastases or suspected presence of scalp metastasis * Subjects with cold sensitivity, cryoglobulinemia, cryofibrinogenemia, or cold migraine pot-traumatic cold dystrophy * Previously received, or scheduled to undergo skull irradiation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety as assessed by CTCAE | Up to 44 weeks from the start of treatment | Safety will be determined by toxicity assessment according to CTCAE |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORShari Goldfarb, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed